151 related articles for article (PubMed ID: 38175659)
1. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US.
Kerekes DM; Frey AE; Prsic EH; Tran TT; Clune JE; Sznol M; Kluger HM; Forman HP; Becher RD; Olino KL; Khan SA
JAMA Oncol; 2024 Mar; 10(3):342-351. PubMed ID: 38175659
[TBL] [Abstract][Full Text] [Related]
2. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US.
Ermer T; Canavan ME; Maduka RC; Li AX; Salazar MC; Kaminski MF; Pichert MD; Zhan PL; Mase V; Kluger H; Boffa DJ
JAMA Netw Open; 2022 Jun; 5(6):e2219535. PubMed ID: 35771575
[TBL] [Abstract][Full Text] [Related]
3. Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US.
Moyers JT; Patel A; Shih W; Nagaraj G
JAMA Netw Open; 2020 Sep; 3(9):e2015656. PubMed ID: 32876684
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Aggressive End-of-Life Care Among Older Adults With Metastatic Cancer Living in Nursing Homes and Community Settings.
Koroukian SM; Douglas SL; Vu L; Fein HL; Gairola R; Warner DF; Schiltz NK; Cullen J; Owusu C; Sajatovic M; Rose J
JAMA Netw Open; 2023 Feb; 6(2):e230394. PubMed ID: 36811860
[TBL] [Abstract][Full Text] [Related]
6. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
[TBL] [Abstract][Full Text] [Related]
7. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
Lamba N; Ott PA; Iorgulescu JB
JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
[TBL] [Abstract][Full Text] [Related]
8. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
9. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life.
Riaz F; Gan G; Li F; Davidoff AJ; Adelson KB; Presley CJ; Adamson BJ; Shaw P; Parikh RB; Mamtani R; Gross CP
JCO Oncol Pract; 2020 Nov; 16(11):e1355-e1370. PubMed ID: 32678688
[TBL] [Abstract][Full Text] [Related]
10. Association of Advance Care Planning Visits With Intensity of Health Care for Medicare Beneficiaries With Serious Illness at the End of Life.
Weissman JS; Reich AJ; Prigerson HG; Gazarian P; Tjia J; Kim D; Rodgers P; Manful A
JAMA Health Forum; 2021 Jul; 2(7):e211829. PubMed ID: 35977213
[TBL] [Abstract][Full Text] [Related]
11. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
12. Association Between Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer.
Sun L; Bleiberg B; Hwang WT; Marmarelis ME; Langer CJ; Singh A; Cohen RB; Mamtani R; Aggarwal C
JAMA Oncol; 2023 Aug; 9(8):1075-1082. PubMed ID: 37270700
[TBL] [Abstract][Full Text] [Related]
13. Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment.
Ramagopalan SV; Popat S; Gupta A; Boyne DJ; Lockhart A; Hsu G; O'Sullivan DE; Inskip J; Ray J; Cheung WY; Griesinger F; Subbiah V
JAMA Netw Open; 2022 Nov; 5(11):e2239874. PubMed ID: 36326765
[TBL] [Abstract][Full Text] [Related]
14. Adoption of Innovative Therapies Across Oncology Practices-Evidence From Immunotherapy.
Carroll CE; Landrum MB; Wright AA; Keating NL
JAMA Oncol; 2023 Mar; 9(3):324-333. PubMed ID: 36602811
[TBL] [Abstract][Full Text] [Related]
15. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting.
Canavan M; Wang X; Ascha M; Miksad R; Showalter TN; Calip G; Gross CP; Adelson K
J Clin Oncol; 2023 Oct; 41(30):4729-4738. PubMed ID: 37339389
[TBL] [Abstract][Full Text] [Related]
16. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer.
Leapman MS; Presley CJ; Zhu W; Soulos PR; Adelson KB; Miksad RA; Boffa DJ; Gross CP
JAMA Netw Open; 2020 Jun; 3(6):e207205. PubMed ID: 32511721
[TBL] [Abstract][Full Text] [Related]
17. Radiation therapy at the end of life in patients with incurable nonsmall cell lung cancer.
Kapadia NS; Mamet R; Zornosa C; Niland JC; D'Amico TA; Hayman JA
Cancer; 2012 Sep; 118(17):4339-45. PubMed ID: 22252390
[TBL] [Abstract][Full Text] [Related]
18. Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy.
Voruganti T; Soulos PR; Mamtani R; Presley CJ; Gross CP
JAMA Oncol; 2023 Mar; 9(3):334-341. PubMed ID: 36701150
[TBL] [Abstract][Full Text] [Related]
19. Concurrent Hospice Care and Cancer-Directed Treatment for Advanced Lung Cancer and Receipt of Aggressive Care at the End of Life in the Veteran's Health Administration.
Presley CJ; Han L; O'Leary JR; Zhu W; Corneau E; Chao H; Shamas T; Rose M; Lorenz K; Levy CR; Mor V; Gross CP
J Palliat Med; 2020 Aug; 23(8):1038-1044. PubMed ID: 32119800
[No Abstract] [Full Text] [Related]
20. Disparities in Care Management During Terminal Hospitalization Among Adults With Metastatic Cancer From 2010 to 2017.
Deeb S; Chino FL; Diamond LC; Tao A; Aragones A; Shahrokni A; Yerramilli D; Gillespie EF; Tsai CJ
JAMA Netw Open; 2021 Sep; 4(9):e2125328. PubMed ID: 34550384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
